The world's first fully superconducting tokamak is soon to produce a discharge of ionized gas or plasma.
EAST is only one-tenth the volume of Japan's JT-60 tokamak, and one-hundredth the expected volume of ITER. It won't produce fusion power, and is designed to study advanced tokamak physics. The first plasma, created from heated hydrogen gas, will probably last for only a few seconds. Still, "it will be a very important step forward," says Toshihide Tsunematsu, director-general of the Naka Fusion Institute of the Japan Atomic Energy Agency, who visited EAST a few weeks ago. The agency owns the JT-60 tokamak.
Eventually, the EAST team aims to hold a plasma for study for as long as 1,000 seconds. In the meantime, the EAST researchers have plenty to work on, says Tsunematsu. They will have to improve key technologies, such as a device to heat the plasma, and be able to effectively control hightemperature plasma for a long period of time. "China will face a real challenge," he says.
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PD-1 could shed light on the subject. So far, he has studied 12 élite controllers, and all have normal levels of PD-1 expression -much lower than those found in most HIV patients.
Still, other scientists caution that the PD-1 story cannot explain everything. PD-1 is found on many cells, not just those that target HIV. So interfering with it may have unpredictable consequences, says Rick Koup, an immunologist at the US National Institute of Allergy and Infectious Diseases (NIAID).
Koup is publishing a paper on the PD-1/ PD-1 ligand interaction in HIV patients on 5 September, in the Journal of Experimental Medicine. His findings indicate that blocking PD-1's interaction with PD-1 ligand may simply prevent T cells from dying, rather than rejuvenating them.
Anthony Fauci, director of the NIAID, agrees that further investigation is needed to follow up the PD-1 findings. "This work is elegant and very carefully done, and from a scientific standpoint it's solid, " he says. "But we've got to be careful we don't make the majestic leap to say: now we've solved the issue of unresponsiveness in people infected with HIV. It may turn out to be that way, but we've got to be cautious. " ■ Erika Check
